VertexPharma wants to transform the treatment of pain. An upcoming sciatica clinical trial readout will be pivotal.

Citi has started coverage of Gilead Sciences (NASDAQ:GILD) and Vertex Pharmaceuticals (NASDAQ:VRTX) at buy saying the former will benefit from short-term growth of Biktarvy (bictegravir, emtricitabine ...

Vertex (VERX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

On Thursday, Vertex Pharmaceuticals earned a positive adjustment to its Relative Strength (RS) Rating, from 68 to 74. Please ...

Vertex (VERX – Research Report), the Technology sector company, was revisited by a Wall Street analyst today. Analyst Chris Quintero from ...

Morgan Stanley analyst Chris Quintero raised the firm’s price target on Vertex (VERX) to $62 from $50 and keeps an Overweight rating on the shares. The firm has greater conviction in Vertex being a ...

Trinasolar, a global leader in smart PV and energy storage solutions, has been awarded the Bankability certificate for its Vertex n-type TOPCon bifacial PV modules by TÜV Rheinland, an independent ...

These are the 300 companies whose success goes beyond profits to include employee and customer sentiment, cybersecurity, ...

Vertex Inc. (NASDAQ:VERX) ("Vertex” or the "Company”), a global provider of tax technology solutions, announced a new survey ...

Vertex Pharmaceuticals continues to excel with strong Q3 results and promising clinical progress, but its valuation may ...

Good day, and welcome to the Vertex Pharmaceuticals third quarter 2024 earnings call. All participants will be in a ...

Vertex achieved its highest level of activity for fiscal 2024 in the current quarter, reporting an adjusted EBITDA (1) of $11.9 million, surpassing the previous company record by $1.0 million. This ...